Skip to main content
Top
Published in: Gut Pathogens 1/2022

Open Access 01-12-2022 | Helicobacter Pylori | Research

Analysis of gastric microbiota and Helicobacter pylori infection in gastroesophageal reflux disease

Authors: Titong Sugihartono, Kartika Afrida Fauzia, Muhammad Miftahussurur, Langgeng Agung Waskito, Purwo Sri Rejeki, Reny I’tishom, Ricky Indra Alfaray, Dalla Doohan, Rizki Amalia, Camilia Metadea Aji Savitri, Yudith Annisa Ayu Rezkitha, Junko Akada, Takashi Matsumoto, Yoshio Yamaoka

Published in: Gut Pathogens | Issue 1/2022

Login to get access

Abstract

Background

We evaluated the microbiota in the stomach of Gastroesophageal Reflux Disease (GERD) patients. We compared Erosive Reflux Disease (ERD) to gastritis and Non-erosive Reflux Disease (NERD) subjects by 16S rRNA approach on gastric biopsy specimens. A total of 197 subjects were included consisting of gastritis (68; 34.52%), ERD (55; 27.92%), and NERD (74; 37.56%). After quality filtering, 187 samples were included for OTU analysis using Qiime2.

Results

We observed a significant difference in alpha diversity (Shannon and Simpson indexes were P = 0.0016 and P = 0.017, respectively). A significant decrease in alpha diversity index was observed in NERD with Helicobacter pylori (H. pylori)-positive subjects than in gastritis (Simpson index P = 0.022; Shannon index P = 0.029), indicating a significant influence of H. pylori on the diversity in the stomach despite the diseases. In H. pylori-negative samples, alpha diversity measurement by the abundance coverage estimates (ACE) and Fisher Test revealed that ERD had significantly lower richness than gastritis and NERD groups (P = 0.00012 and P = 0.00043, respectively). Anaerobacillus sp. could only be found in ERD patients by LEFse analysis.

Conclusions

The presence of ERD could alter microbiome diversity. A negative correlation between H. pylori and ERD is shown in this microbiome study but not in NERD.
Appendix
Available only for authorised users
Literature
1.
go back to reference El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–80.CrossRef El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–80.CrossRef
2.
go back to reference Farup C, Kleinman L, Sloan S, Ganoczy D, Chee E, Lee C, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med. 2001;161(1):45–52.CrossRef Farup C, Kleinman L, Sloan S, Ganoczy D, Chee E, Lee C, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med. 2001;161(1):45–52.CrossRef
3.
go back to reference Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA. 2002;287(15):1972–81.CrossRef Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA. 2002;287(15):1972–81.CrossRef
4.
go back to reference Badillo R, Francis D. Diagnosis and treatment of gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther. 2014;5(3):105–12.CrossRef Badillo R, Francis D. Diagnosis and treatment of gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther. 2014;5(3):105–12.CrossRef
6.
go back to reference Dieterich W, Schink M, Zopf Y. Microbiota in the gastrointestinal tract. Med Sci. 2018;6(4):116. Dieterich W, Schink M, Zopf Y. Microbiota in the gastrointestinal tract. Med Sci. 2018;6(4):116.
7.
go back to reference Snider EJ, Compres G, Freedberg DE, Khiabanian H, Nobel YR, Stump S, et al. Alterations to the esophageal microbiome associated with progression from Barrett’s esophagus to esophageal adenocarcinoma. Cancer Epidemiol Prev Biomarkers. 2019;28(10):1687–93.CrossRef Snider EJ, Compres G, Freedberg DE, Khiabanian H, Nobel YR, Stump S, et al. Alterations to the esophageal microbiome associated with progression from Barrett’s esophagus to esophageal adenocarcinoma. Cancer Epidemiol Prev Biomarkers. 2019;28(10):1687–93.CrossRef
8.
go back to reference Schubert ML. Gastric secretion. Curr Opin Gastroenterol. 2005;21(6):636–43.CrossRef Schubert ML. Gastric secretion. Curr Opin Gastroenterol. 2005;21(6):636–43.CrossRef
9.
go back to reference Oleskin AV, Shenderov BA. Neuromodulatory effects and targets of the SCFAs and gasotransmitters produced by the human symbiotic microbiota. Microb Ecol Health Dis. 2016;27(1):30971.PubMed Oleskin AV, Shenderov BA. Neuromodulatory effects and targets of the SCFAs and gasotransmitters produced by the human symbiotic microbiota. Microb Ecol Health Dis. 2016;27(1):30971.PubMed
10.
go back to reference Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology. 2009;137(2):588–97.CrossRef Yang L, Lu X, Nossa CW, Francois F, Peek RM, Pei Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology. 2009;137(2):588–97.CrossRef
11.
go back to reference Gantuya B, El Serag HB, Matsumoto T, Ajami NJ, Uchida T, Oyuntsetseg K, et al. Gastric mucosal microbiota in a Mongolian population with gastric cancer and precursor conditions. Aliment Pharmacol Ther. 2020;51(8):770–80.CrossRef Gantuya B, El Serag HB, Matsumoto T, Ajami NJ, Uchida T, Oyuntsetseg K, et al. Gastric mucosal microbiota in a Mongolian population with gastric cancer and precursor conditions. Aliment Pharmacol Ther. 2020;51(8):770–80.CrossRef
12.
go back to reference Xie T, Cui X, Zheng H, Chen D, He L, Jiang B. Meta-analysis: eradication of: Helicobacter pylori: infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2013;25(10):1195–205.PubMed Xie T, Cui X, Zheng H, Chen D, He L, Jiang B. Meta-analysis: eradication of: Helicobacter pylori: infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2013;25(10):1195–205.PubMed
13.
go back to reference Miftahussurur M, Doohan D, Nusi IA, Adi P, Rezkitha YAA, Waskito LA, et al. Gastroesophageal reflux disease in an area with low Helicobacter pylori infection prevalence. PLoS ONE. 2018;13(11): e0205644.CrossRef Miftahussurur M, Doohan D, Nusi IA, Adi P, Rezkitha YAA, Waskito LA, et al. Gastroesophageal reflux disease in an area with low Helicobacter pylori infection prevalence. PLoS ONE. 2018;13(11): e0205644.CrossRef
14.
go back to reference den Hollander WJ, Sostres C, Kuipers EJ, Lanas A. Helicobacter pylori and nonmalignant diseases. Helicobacter. 2013;18:24–7.CrossRef den Hollander WJ, Sostres C, Kuipers EJ, Lanas A. Helicobacter pylori and nonmalignant diseases. Helicobacter. 2013;18:24–7.CrossRef
15.
go back to reference Miftahussurur M, Waskito LA, El-Serag HB, Ajami NJ, Nusi IA, Syam AF, et al. Gastric microbiota and Helicobacter pylori in Indonesian population. Helicobacter. 2020;25(4): e12695.CrossRef Miftahussurur M, Waskito LA, El-Serag HB, Ajami NJ, Nusi IA, Syam AF, et al. Gastric microbiota and Helicobacter pylori in Indonesian population. Helicobacter. 2020;25(4): e12695.CrossRef
16.
go back to reference Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med. 1998;104(3):252–8.CrossRef Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med. 1998;104(3):252–8.CrossRef
17.
go back to reference Shi Y-C, Cai S-T, Tian Y-P, Zhao H-J, Zhang Y-B, Chen J, et al. Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease. Genomics Proteomics Bioinformatics. 2019;17(1):52–63.CrossRef Shi Y-C, Cai S-T, Tian Y-P, Zhao H-J, Zhang Y-B, Chen J, et al. Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease. Genomics Proteomics Bioinformatics. 2019;17(1):52–63.CrossRef
18.
go back to reference Herregods T, Bredenoord A, Smout A. Pathophysiology of gastroesophageal reflux disease: new understanding in a new era. Neurogastroenterol Motil. 2015;27(9):1202–13.CrossRef Herregods T, Bredenoord A, Smout A. Pathophysiology of gastroesophageal reflux disease: new understanding in a new era. Neurogastroenterol Motil. 2015;27(9):1202–13.CrossRef
19.
go back to reference DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis. 2016;22(5):1137–50.CrossRef DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis. 2016;22(5):1137–50.CrossRef
20.
go back to reference Andersson AF, Lindberg M, Jakobsson H, Bäckhed F, Nyrén P, Engstrand L. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS ONE. 2008;3(7): e2836.CrossRef Andersson AF, Lindberg M, Jakobsson H, Bäckhed F, Nyrén P, Engstrand L. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS ONE. 2008;3(7): e2836.CrossRef
21.
go back to reference Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci. 2006;103(3):732–7.CrossRef Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci. 2006;103(3):732–7.CrossRef
22.
go back to reference Zhang X, Li C, Cao W, Zhang Z. Alterations of gastric microbiota in gastric cancer and precancerous stages. Front Cell Infect Microbiol. 2021;11:69. Zhang X, Li C, Cao W, Zhang Z. Alterations of gastric microbiota in gastric cancer and precancerous stages. Front Cell Infect Microbiol. 2021;11:69.
23.
go back to reference Corning B, Copland AP, Frye JW. The esophageal microbiome in health and disease. Curr Gastroenterol Rep. 2018;20(8):1–7.CrossRef Corning B, Copland AP, Frye JW. The esophageal microbiome in health and disease. Curr Gastroenterol Rep. 2018;20(8):1–7.CrossRef
24.
go back to reference Cani PD, Jordan BF. Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer. Nat Rev Gastroenterol Hepatol. 2018;15(11):671–82.CrossRef Cani PD, Jordan BF. Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer. Nat Rev Gastroenterol Hepatol. 2018;15(11):671–82.CrossRef
25.
go back to reference Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei W-Q, Qiao Y-L, et al. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol: WJG. 2011;17(39):4421.CrossRef Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei W-Q, Qiao Y-L, et al. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol: WJG. 2011;17(39):4421.CrossRef
26.
go back to reference Llorente C, Schnabl B. The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol. 2015;1(3):275–84.CrossRef Llorente C, Schnabl B. The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol. 2015;1(3):275–84.CrossRef
27.
go back to reference Zhou J, Shrestha P, Qiu Z. Distinct Microbiota Dysbiosis in Patients with Non-Erosive Reflux Disease and Esophageal Adenocarcinoma. 2020;9:7. Zhou J, Shrestha P, Qiu Z. Distinct Microbiota Dysbiosis in Patients with Non-Erosive Reflux Disease and Esophageal Adenocarcinoma. 2020;9:7.
28.
go back to reference Fass R. Non-erosive reflux disease (NERD) and erosive esophagitis-a spectrum of disease or special entities? Z Gastroenterol. 2007;45(11):1156–63.CrossRef Fass R. Non-erosive reflux disease (NERD) and erosive esophagitis-a spectrum of disease or special entities? Z Gastroenterol. 2007;45(11):1156–63.CrossRef
29.
go back to reference Zimmerman J. Extraintestinal symptoms in irritable bowel syndrome and inflammatory bowel diseases: nature, severity, and relationship to gastrointestinal symptoms. Dig Dis Sci. 2003;48(4):743–9.CrossRef Zimmerman J. Extraintestinal symptoms in irritable bowel syndrome and inflammatory bowel diseases: nature, severity, and relationship to gastrointestinal symptoms. Dig Dis Sci. 2003;48(4):743–9.CrossRef
30.
go back to reference Jones S, Clague R, Eldridge J, Jones D. Serological evidence of infection with Helicobacter pylori may predict gastrointestinal intolerance to non-steroidal anti-inflammatory drug (NSAID) treatment in rheumatoid arthritis. Rheumatology. 1991;30(1):16–20.CrossRef Jones S, Clague R, Eldridge J, Jones D. Serological evidence of infection with Helicobacter pylori may predict gastrointestinal intolerance to non-steroidal anti-inflammatory drug (NSAID) treatment in rheumatoid arthritis. Rheumatology. 1991;30(1):16–20.CrossRef
31.
go back to reference Syam AF, Miftahussurur M, Makmun D, Nusi IA, Zain LH, Zulkhairi X, et al. Risk Factors and Prevalence of Helicobacter pylori in Five Largest Islands of Indonesia: A Preliminary Study. PLoS ONE. 2015;10(11):e0140186.CrossRef Syam AF, Miftahussurur M, Makmun D, Nusi IA, Zain LH, Zulkhairi X, et al. Risk Factors and Prevalence of Helicobacter pylori in Five Largest Islands of Indonesia: A Preliminary Study. PLoS ONE. 2015;10(11):e0140186.CrossRef
32.
go back to reference Gantuya B, El Serag HB, Saruuljavkhlan B, Azzaya D, Matsumoto T, Uchida T, et al. Advantage of 16S rRNA amplicon sequencing in Helicobacter pylori diagnosis. Helicobacter. 2021;26(3): e12790.CrossRef Gantuya B, El Serag HB, Saruuljavkhlan B, Azzaya D, Matsumoto T, Uchida T, et al. Advantage of 16S rRNA amplicon sequencing in Helicobacter pylori diagnosis. Helicobacter. 2021;26(3): e12790.CrossRef
33.
go back to reference Kim J, Kim N, Jo HJ, Park JH, Nam RH, Seok YJ, et al. An appropriate cutoff value for determining the colonization of Helicobacter pylori by the pyrosequencing method: comparison with conventional methods. Helicobacter. 2015;20(5):370–80.CrossRef Kim J, Kim N, Jo HJ, Park JH, Nam RH, Seok YJ, et al. An appropriate cutoff value for determining the colonization of Helicobacter pylori by the pyrosequencing method: comparison with conventional methods. Helicobacter. 2015;20(5):370–80.CrossRef
34.
go back to reference Gantuya B, El-Serag HB, Matsumoto T, Ajami NJ, Oyuntsetseg K, Azzaya D, et al. Gastric microbiota in Helicobacter pylori-negative and-positive gastritis among high incidence of gastric cancer area. Cancers. 2019;11(4):504.CrossRef Gantuya B, El-Serag HB, Matsumoto T, Ajami NJ, Oyuntsetseg K, Azzaya D, et al. Gastric microbiota in Helicobacter pylori-negative and-positive gastritis among high incidence of gastric cancer area. Cancers. 2019;11(4):504.CrossRef
35.
go back to reference Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37(8):852–7.CrossRef Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37(8):852–7.CrossRef
36.
go back to reference Yilmaz P, Parfrey LW, Yarza P, Gerken J, Pruesse E, Quast C, et al. The SILVA and “all-species living tree project (LTP)” taxonomic frameworks. Nucleic Acids Res. 2014;42(D1):D643–8.CrossRef Yilmaz P, Parfrey LW, Yarza P, Gerken J, Pruesse E, Quast C, et al. The SILVA and “all-species living tree project (LTP)” taxonomic frameworks. Nucleic Acids Res. 2014;42(D1):D643–8.CrossRef
37.
go back to reference Katoh K, Kuma K, Toh H, Miyata T. MAFFT version 5: improvement in accuracy of multiple sequence alignment. Nucleic Acids Res. 2005;33(2):511–8.CrossRef Katoh K, Kuma K, Toh H, Miyata T. MAFFT version 5: improvement in accuracy of multiple sequence alignment. Nucleic Acids Res. 2005;33(2):511–8.CrossRef
38.
go back to reference Price MN, Dehal PS, Arkin AP. FastTree 2–approximately maximum-likelihood trees for large alignments. PLoS ONE. 2010;5(3): e9490.CrossRef Price MN, Dehal PS, Arkin AP. FastTree 2–approximately maximum-likelihood trees for large alignments. PLoS ONE. 2010;5(3): e9490.CrossRef
39.
go back to reference Oksanen J, Blanchet FG, Friendly M, Kindt R, Legendre P, McGlinn D, et al. vegan package (Community Ecology Package). 2.5–7 ed. https://CRAN.R-project.org/package=vegan: R programme; 2016. p. Ordination methods, diversity analysis and other functions for community and vegetation ecologists. License: GPL-2. Oksanen J, Blanchet FG, Friendly M, Kindt R, Legendre P, McGlinn D, et al. vegan package (Community Ecology Package). 2.5–7 ed. https://​CRAN.​R-project.​org/​package=​vegan: R programme; 2016. p. Ordination methods, diversity analysis and other functions for community and vegetation ecologists. License: GPL-2.
Metadata
Title
Analysis of gastric microbiota and Helicobacter pylori infection in gastroesophageal reflux disease
Authors
Titong Sugihartono
Kartika Afrida Fauzia
Muhammad Miftahussurur
Langgeng Agung Waskito
Purwo Sri Rejeki
Reny I’tishom
Ricky Indra Alfaray
Dalla Doohan
Rizki Amalia
Camilia Metadea Aji Savitri
Yudith Annisa Ayu Rezkitha
Junko Akada
Takashi Matsumoto
Yoshio Yamaoka
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Gut Pathogens / Issue 1/2022
Electronic ISSN: 1757-4749
DOI
https://doi.org/10.1186/s13099-022-00510-3

Other articles of this Issue 1/2022

Gut Pathogens 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.